Dr. Eugene De Juan

Dr. Eugene de Juan, Jr. is the founder of ForSight Labs where he participates as an active inventor and advisor in early-stage ophthalmic opportunities. Dr. de Juan, Jr. splits his time between ForSight Labs and UCSF Medical Center. He holds the "Jean Kelly Stock Distinguished Chair" in Ophthalmology. UCSF recruited Dr. de Juan for this special role to augment translation of the many ideas being developed within the academic center. He continues to see patients and teach at UCSF. Dr. de Juan, Jr., has participated in the development of a number of ophthalmology’s most exciting new technologies with over 100 products and founding a number of venture funded companies, including Second Sight, InnoRx (bought by Surmodics in 2005), and ForSight Labs’ companies Transcend Medical, founded in 2005, NexisVision, Vision 4, 5 and recently Vision 6. Prior to moving to San Francisco, Dr. de Juan, Jr., was a professor of ophthalmology at the University of Southern California and chief executive officer of the Doheny Retina Institute, focusing on innovative techniques for treating blinding retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants and other new procedures, medicines and instruments. Dr. de Juan served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine where he was co-director of Vitreoretinal Service, director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992 he was a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology. Dr. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. He served an internship at University of South Alabama Medical Center followed by a residency at the Wilmer Ophthalmological Institute in Baltimore, Maryland, and a fellowship in vitreoretinal surgery at Duke University. He holds patents on over 100 medical devices and is responsible for more than 250 academic publications.